NCT01767987View on ClinicalTrials.gov

Ranolazine Cardioprotection in PCI

PHASE2TerminatedINTERVENTIONAL

Enrollment

6

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions

Acute Coronary Syndrome

Interventions

DRUG

Ranolazine

Drug: Ranolazine 1000 mg Oral dose twice per day for 3 days leading up to PCI

DRUG

Placebo

Drug: Placebo Oral dose twice per day for 3 days leading up to PCI

Trial Locations (1)

45429

Kettering Medical Center, Kettering

Sponsors

Collaborators (1)

Gilead Sciences

All Listed Sponsors

collaborator

Gilead Sciences

INDUSTRY

lead

Harvey Hahn

OTHER